Lọc theo
For patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), continued use of metformin for at least 6 months when eGFR falls below 30 mL/min/1.73m2 appears to yield a small but significant decrease in all-cause mortality, according to a nationwide observational cohort study.
In people with obesity but without diabetes, starting semaglutide treatment appears to be influenced by sociodemographic, health care, and clinical factors, according to a retrospective observational cohort study.
The incident use of gabapentin, compared with duloxetine, does not seem to increase fall-related visits among older adults, according to a study.
Among patients on dialysis, the use of denosumab reduced the risk for fractures by as much as 45 percent but increased the risk for major adverse cardiovascular events (MACE) by 36 percent when compared with oral bisphosphonates, a study has shown.
Herbal intervention with Matricaria chamomilla, known as chamomile, appears to alleviate menopausal symptoms, as shown in the results of a triple-blind clinical trial.
The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.
Long-term kidney outcomes in type 2 diabetes (T2D) are similar between empagliflozin- and dapagliflozin-treated patients, aligning with current clinical practice guidelines that do not favour one SGLT2 inhibitor over the other, according to a study.
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly lowers blood pressure (BP) in obese or overweight patients, according to a study. This beneficial effect persists across diabetic status, duration of treatment, and route of administration.
In the management of type 2 diabetes (T2D) in adults who are naïve to insulin, once-weekly efsitora alfa compares favourably with once-daily degludec in terms of lowering glycated haemoglobin levels, according to an open-label phase III study.
Once-daily treatment with etavopivat results in lower rates of annualized vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD) compared with placebo, according to the HIBISCUS trial presented at ASH 2024.
